CLOs on the Move

Clinical ink

www.clinicalink.com

 
Clinical ink is the global life science company that brings data, technology, and patient-centric research together. Our deep therapeutic-area expertise, coupled with Direct Data Capture, eCOA, eConsent, telehealth, neurocognitive testing, and digital biomarkers advancements, drive the industry standard for data precision and usher in a new generation of clinical trials. By harnessing digital data, we power sponsors, CROs, researchers, and patients to recenter decentralized trials and rewrite the clinical development experience.
  • Number of Employees: 250-1000
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Odan Laboratories

Odan Laboratories is a Pointe-Claire, QC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

SST Corporation

SST Corporation is a Clifton, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

UltraFiltronics Corp

UltraFiltronics Corp is a Randolph, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Assertio Therapeutics

Assertio Therapeutics, Inc. is an American specialty pharmaceutical company.

Vernalis

Vernalis plc is a revenue generating development stage pharmaceutical company with one marketed product, frovatriptan, and a broad pipeline of research and development programmes. The business model is a balance between risk and innovation with the aim of creating value through a focused and disciplined strategy. An exclusive development and licensing agreement with Tris Pharma to develop multiple novel products focussed on the US prescription cough cold market is the platform for Vernalis to build a profitable and cash generative commercial business in the US. These novel products are low risk, late stage and differentiated for an unmet need. Value is also being extracted from the legacy NCE pipeline where the model is to selectively invest and then partner these programmes, earning milestones and royalties as partners progress them at their expense. Vernalis also exploits its significant expertise in fragment and structure based drug discovery by entering into collaborations with larger pharmaceutical companies. Its technologies and capabilities have been endorsed, over the last five years, through collaborations with leading pharmaceutical companies, including Biogen Idec, Endo, GSK, Genentech, Lundbeck, Menarini, Novartis, Servier and Tris Pharma.